Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
OHSU Knight Cancer Institute
Barbara Ann Karmanos Cancer Institute
St. Jude Children's Research Hospital
Barbara Ann Karmanos Cancer Institute
Northwestern University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Bristol-Myers Squibb
University of Massachusetts, Worcester
Duke University
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Bristol-Myers Squibb